On-Demand Workshop & Scientific Posters Available Now:

Title: Clinical impact of the EXENT® solution*, an innovation for immunoglobulin identification & quantification 
Chair: Stephen Harding, Chief Scientific Officer, The Binding Site, part of Thermo Fisher Scientific, UK

Part 1 - Development & performance of the fully automated EXENT platform*

Speaker: Mark Perkins, EXENT Portfolio leader, The Binding Site, part of Thermo Fisher Scientific UK

Part 2 - How the EXENT solution* could support monoclonal gammopathy patients in clinical practice 

Speaker: Dr. Noemí Puig, MD, PhD Consultant Physician at the Hematology Department, Hospital Universitario de Salamanca, Spain

Part 3 - Case Study: EXENT system* from the laboratory to the clinic

Speaker: Dr. Cristina Agulló Roca, Clinical Laboratory Specialist, Hospital Universitario de Salamanca, Spain

Presented Scientific Posters:

Poster 1: THE PREVALENCE OF BICLONAL GAMMOPATHIES IS HIGHER THAN PREVIOUSLY REPORTED WHEN ANALYZED BY MALDI-TOF MASS SPECTROMETRY

J. Birtwistle¹, O.Berlanga¹, S. Allen¹, G. Malin¹, G. Lakos¹

1. The Binding Site, part of Thermo Fisher Scientific, Birmingham, UK

Poster 2: UTILITY OF THE EXENT® IMMUNOGLOBULIN (GAM) ASSAY* IN A REGIONAL CLINICAL IMMUNOLOGY SERVICE LABORATORY - A COMPARISON EXERCISE OF CHALLENGING SAMPLES. 

W. Bermingham¹, N. Wright², O. Berlanga², G. Wallis², S. North², J. Ashby², S. Harding², A. Huissoon¹

1. Immunology, Heartlands Hospital, University Hospitals, Birmingham, UK

2. The Binding Site, part of Thermo Fisher Scientific, Birmingham, UK

Poster 3: ANALYTICAL PERFORMANCE CHARACTERISTICS OF THE EXENT® SOLUTION* FOR IDENTIFICATION AND QUANTITATION OF MONOCLONAL IMMUNOGLOBULINS

D. Matters¹, D. Mcentee¹, R. Stanton¹, S. Ijaz¹, A. Khalid¹, D. Barnidge², L. Ouverson², D. Sakrikar², J. Ashby¹, N. Marrot¹, S. North¹

1. The Binding Site, part of Thermo Fisher Scientific, Birmingham, UK

2. The Binding Site, part of Thermo Fisher Scientific, Rochester, MN, US 

*This product has not been cleared for sale in the USA, EU or other countries and is not commercially available and future commercial availability cannot be guaranteed.